作者
Rose A Gubitosi-Klug, Barbara H Braffett, Susan Hitt, Valerie Arends, Diane Uschner, Kimberly Jones, Lisa Diminick, Amy B Karger, Andrew D Paterson, Delnaz Roshandel, Santica Marcovina, John M Lachin, Michael Steffes, Jerry P Palmer
发表日期
2021/2/1
期刊
The Journal of clinical investigation
卷号
131
期号
3
出版商
American Society for Clinical Investigation
简介
BACKGROUND
We investigated residual β cell function in Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study participants with an average 35-year duration of type 1 diabetes mellitus (T1DM).
METHODS
Serum C-peptide was measured during a 4-hour mixed-meal tolerance test. Associations with metabolic outcomes and complications were explored among nonresponders (all C-peptide values after meal <0.003 nmol/L) and 3 categories of responders, classified by peak C-peptide concentration (nmol/L) as high (>0.2), intermediate (>0.03 to ≤0.2), and low (≥ 0.003 to ≤0.03).
RESULTS
Of the 944 participants, 117 (12.4%) were classified as responders. Residual C-peptide concentrations were associated with higher DCCT baseline concentrations of stimulated C-peptide (P value for trend …
学术搜索中的文章
RA Gubitosi-Klug, BH Braffett, S Hitt, V Arends… - The Journal of clinical investigation, 2021